In a report released today, Jay Olson from Oppenheimer upgraded Ovid Therapeutics to a Buy, with a price target of $7.00. The company’s shares closed yesterday at $1.58.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Olson is a 4-star analyst with an average return of 8.4% and a 43.60% success rate. Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Madrigal Pharmaceuticals, and Gain Therapeutics.
Currently, the analyst consensus on Ovid Therapeutics is a Strong Buy with an average price target of $4.33.
The company has a one-year high of $2.01 and a one-year low of $0.24. Currently, Ovid Therapeutics has an average volume of 3.06M.
Read More on OVID:
Disclaimer & DisclosureReport an Issue
- Ovid Therapeutics initiated with an Outperform at Oppenheimer
- Ovid Therapeutics Secures $175.1M in Private Placement
- Morning Movers: Apple shares slip following Jefferies downgrade
- Ovid Therapeutics prices private placement up to $175M in gross proceeds
- Ovid Therapeutics announces results for Phase 1 study of OV329
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
